MedTrace Logo

A Study To Estimate The Relative Bioavailability Of PF-00258210 Administered Alone Or In Combination With PF-00610355

NCT01043276 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-04-27

No results posted yet for this study

Summary

The purpose of this study if to investiagte the time course of PF-00258210 plasma concentration in the presence or absence of PF-00610335 administered via oral inhalation using dry powder inhalers

Conditions

Interventions

DRUG

Treatment A

PF-00258210 220 µg using inhaler A

DRUG

Treatment B

PF-00258210 220 µg using inhaler A and 450 µg PF-00610335 using inhaler A

DRUG

Treatment C

PF-00258210 440 µg and 450 µg PF-00610335 using inhaler A

DRUG

Treatment D

PF-00258210 350 µg and 450 µg PF-00610335 using inhaler A

DRUG

Treatment E

PF-00258210 220 µg using inhaler B

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01043276 on ClinicalTrials.gov